USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Strategic Overview of Patenting Activity in Pharma Sector of BRIC Countries
Strategic Overview of Patenting Activity in Pharma Sector of BRIC Countries
Patenting Trends, IP Policy Developments, and Strategic Insights
RELEASE DATE
20-Sep-2015
20-Sep-2015
REGION
North America
North America
Research Code: D69A-01-00-00-00
SKU: LS00085-NA-MR_16926
$4,950.00
Special Price $3,712.50 save 25 %
In stock
SKU
LS00085-NA-MR_16926
Description
As developed markets are starting to witness slower growth rate; emerging markets, witnessing higher growth rate, are becoming key driver of revenue growth for multinational pharma companies. Much of this growth in Pharma sector of emerging markets is likely to be driven by BRIC, Mexico, and Turkey. This research service aims to highlight opportunities and risks in pharma sector of BRIC countries from a patenting perspective. This report also provides an overview of recent IP policy related developments and its business impact.
Table of Contents
Research Methodology
Active Patent Stock of “Big Pharma” Companies in BRIC Countries
Patenting TrendsPharmaceuticals Sector–India
Patenting Activity at Indian Patent Office (IPO) in Pharma Sector
Patenting Activity by Indian Inventors GloballyInventor Geographical Location: IndiaPatent Offices Coverage: Global
IP Policy Update: Recent Case Studies
Case Study 1: Novartis vs. Cancer Patients Aid Association (CPAA)
Case Study 2: Bayer vs. Natco
Patenting TrendsPharmaceuticals Sector–China
Patenting Activity at Chinese Patent Office (SIPO) in Pharma Sector
Patenting activity by Chinese Inventors GloballyInventor Geographical Location: ChinaPatent Offices Coverage: Global
Patenting TrendsPharmaceuticals Sector–Brazil
Patenting Activity in Pharma Sector at Brazilian Patent Office (INPI)
Patenting Activity by Brazilian Inventors GloballyInventor Geographical Location: BrazilPatent Offices Coverage: Global
Patenting TrendsPharmaceuticals Sector–Russia
Patenting Activity in Pharma Sector at Russian Patent Office
Appendix
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research service evaluates the US market for the pharmaceutical management of AMD, DME, and RVO from 2009 to 2017, with 2012 as the base year. Segmentation by disorder is provided. Included are products on the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.
| No Index | No |
|---|---|
| Podcast | No |
| Author | Manmohan Singh |
| WIP Number | D69A-01-00-00-00 |
| Is Prebook | No |